Glenmark receives tentative approval by USFDA for Azelaic Acid Gel

17 Feb 2016 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for its Azelaic Acid Gel, 15%, the generic version of Finacea Topical Gel, 15% of Bayer Healthcare. Glenmark will market this product upon receiving final approval of its Azelaic Acid Gel, 15% ANDA. The patent listed in the Orange Book for Finacea Topical Gel, 15% is scheduled to expire on November 18, 2018.

According to IMS Health sales data for the 12 month period ending December 2015, the Finacea market achieved annual sales of approximately $128.0 million.

Glenmark’s current portfolio consists of 106 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1237.10 11.85 (0.97%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.